Coverage dated November 7, 2025

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Headline from WFMZ Allentown

NEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss

WFMZ Allentown's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

6 articles, oldest first.

WFMZ Allentown
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk (opens WFMZ Allentown)
Published Nov 7, 2025
WFMZ Allentown's feed description
NEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss
FOX Business
Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition (opens FOX Business)
Published Nov 7, 2025
FOX Business's feed description
Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, beating Danish rival Novo Nordisk following a fierce bidding war.
New York Post
Pfizer wins $10 billion bidding war for obesity drug developer (opens New York Post)
Published Nov 7, 2025
New York Post's feed description
Drugmaker Pfizer secured a $10 billion deal for obesity drug developer Metsera, beating out Danish rival Novo Nordisk.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.